HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Beauty Farm Medical (BFM HK): Expectations Are Flying Too High; 1H23 Result Will Set the Path

Imeik Technology Development (300896.CH) - The Valuation Bubble?

ClouDr Group (9955.HK) - Positive Profit Alert for 2022, Thoughts on Business Model and the Concerns

Bloomage Biotechnology (688363.CH) - Positioning and Strategic Layout Imply Strong Upside Potential

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Beauty Farm Medical and Health Industry / Equity Capital Markets

Beauty Farm Medical and Health Industry (BFM HK)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/beauty-farm-medical-and-health-industry-inc" target="_blank" data-smartkarma-citation="entities:35923:1" rel="noopener">Beauty Farm Medical and Health Industry (BFM HK)</a>’s solid growth has indicated that its business model works. But the industry tightening regulation and potential policy risk are our concerns.</li>
<li>As a downstream company in this industry, we are conservative about Beauty Farm’s profitability. Its profit space could be limited. The Company has weak bargaining power in the whole industrial chain.</li>
<li>Beauty Farm's performance could continue to be under pressure due to weak recovery of domestic demand after three years of the pandemic, especially those non-rigid consumption demand. </li>
</ul>



Beauty Farm Medical and Health Industry (BFM HK)’s solid growth has indicated that its business model works. But the industry tightening regulation and potential policy risk are our concerns.
As a downstream company in this industry, we are conservative about Beauty Farm’s profitability. Its profit space could be limited. The Company has weak bargaining power in the whole industrial chain.
Beauty Farm's performance could continue to be under pressure due to weak recovery of domestic demand after three years of the pandemic, especially those non-rigid consumption demand. 


Raily Aesthetic Medicine International Holdings Limited (2135 HK)

Raily Aesthetic Medicine International Holdings Limited

Imeik Technology Development C (300896 CH)

Pre-IPO Beauty Farm Medical and Health Industry - Hard to Make Money Due to Industry Characteristics